New Approaches to the Treatment of Recurrent Small Cell Lung Cancer
September 19, 2018 | Online

Overview

Small cell lung cancer (SCLC) remains a challenging disease to treat, especially following relapse. However, new treatment options and potential biomarkers have emerged, including a role for immunotherapy in this disease.  In this presentation, Dr. Byers will provide a comprehensive review of the evolving landscape of SCLC treatment - with a focus on the management of patients with recurrent disease.

GOAL & PURPOSE:

  • Identify and discuss recent data and current clinical research evaluating the efficacy and safety of immunotherapeutic agents in the treatment of recurrent SCLC.
  • Assess those clinical research findings that are most relevant to treating clinicians.
  • Appraise the utility of immunotherapy in the management of recurrent SCLC and its evolutionary role in current treatment algorithms.

What you should expect to learn

After attending this webinar, learners will:

  • Provide a comprehensive review of the current treatment landscape for recurrent small cell lung cancer (SCLC).
  • Update scientific progress in the discovery and use of new biomarkers.
  • Appraise the clinical role for immunotherapy in the treatment of recurrent SCLC.
  • Discuss the incorporation of immunotherapy into treatment paradigms.
  • Identify ongoing clinical trials that are likely to impact patient care in the near future.

Lauren Averett Byers, MD
Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston Texas

 Ramaswamy Govindan, MD - Program Chair

Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Contact